Abstracts tagged "methotrexate (MTX)"

Abstract Number: 1655 • 2018 ACR/ARHP Annual Meeting
Achieving Remission in Psoriatic Arthritis By Early Initiation of TNF Inhibition: A Double-Blind, Randomized, Placebo-Controlled Trial of Golimumab + Methotrexate Versus Placebo + Methotrexate
Leonieke van Mens¹, Jet de Jong², Inka Fluri¹, Marleen van de Sande³, Michael Nurmohamed⁴, M.R. Kok⁵, Arno van Kuijk⁶ and Dominique Baeten², ¹Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Clinical Immunology & Rheumatology, ARC | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁴Rheumatology, Reade, Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, ⁵Rheumatology, Maasstad Ziekenhuis, Rotterdam, Netherlands, ⁶Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands
Background/Purpose: In inflammatory arthritis such as RA, early initiation of highly effective targeted treatments is a successful strategy to aim for sustained remission.1 Here we…
Abstract Number: 566 • 2018 ACR/ARHP Annual Meeting
Capillary Blood Based Methotrexate Polyglutamate Assay for Monitoring Low Dose Methotrexate Therapy in Rheumatic Diseases
Thierry Dervieux¹, Kelley Brady¹, Deborah Stimson¹, Ying Qu¹, Tyler O'Malley¹, Robert Apilado¹, Smitha Reddy², Puja Chitkara³, John Conklin¹, Roberta Alexander¹ and Claudia Ibarra¹, ¹Exagen Diagnostics, Inc., Vista, CA, ²Arthritis Care and Research Center, San Diego, CA, ³Center for Arthritis and Rheumatologic Excellence, Chula Vista, CA
Background/Purpose: The red blood cell (RBC) Methotrexate (MTX) polyglutamate (MTXPG3) assay is a helpful therapeutic drug monitoring (TDM) tool in autoimmune rheumatic diseases. Our objective…
Abstract Number: 1859 • 2018 ACR/ARHP Annual Meeting
The Prognostic Value of Autoantibody Isotypes for Predicting Therapeutic Responses to Methotrexate in Patients with Rheumatoid Arthritis
Daniela Sieghart¹, Alexander Platzer², Farideh Alasti², Paul Studenic³, Maresa Grundhuber⁴, Sascha Swiniarski⁴, Stephan Blüml², Helmuth Haslacher⁵, Josef S. Smolen⁶ and Günter Steiner¹, ¹Division of Rheumatology, Department of Internal Medicine III, Medical University Vienna, Austria, Vienna, Austria, ²Division of Rheumatology, Department of Internal Medicine III, Medical University Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Thermo Fisher Scientific, Freiburg, Germany, Freiburg, Germany, ⁵Department of Laboratory Medicine, Medical University Vienna, Vienna, Austria, ⁶Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) are the most specific diagnostic markers of rheumatoid arthritis (RA). Lately we showed that the determination…
Abstract Number: 572 • 2018 ACR/ARHP Annual Meeting
Combining Tocilizumab with Methotrexate Improves Sustainability. Real World Evidence Report from Quebec Database Rhumadata®
Denis Choquette¹, Louis Bessette², Jacques Brown², Boulos Haraoui¹, Frédéric Massicotte¹, Jean-Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard¹, Diane Sauvageau¹, Angèle Turcotte², Édith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Rheumatology, Centre de l'Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada
Background/Purpose: Biologic therapy targeting TNF have consistently demonstrated better efficacy and effectiveness when combined with a conventional synthetic DMARD (csDMARD), most frequently methotrexate. Although pre-clinical…
Abstract Number: 2138 • 2018 ACR/ARHP Annual Meeting
Real-World Evaluation of Treatment Patterns of Methotrexate Users in Psoriatic Arthritis
Brian Ung¹, Dionne Hines², Sandhya Mehta¹, Corey Pelletier¹, Xin Wang² and Rolin Wade², ¹Celgene Corporation, Summit, NJ, ²IQVIA, Durham, NC
Background/Purpose: Methotrexate (MTX) is commonly used to treat psoriatic arthritis (PsA), yet data supporting its effectiveness in PsA are limited. This analysis describes real-world dosing,…
Abstract Number: 581 • 2018 ACR/ARHP Annual Meeting
Comparative Analysis of Outcomes Among Patients with Rheumatoid Arthritis Initiating Tofacitinib in Combination with Oral MTX Who Discontinue, Interrupt, or Persist with MTX
Stanley Cohen¹, Boulos Haraoui², Jeffrey R. Curtis³, Timothy Smith⁴, John Woolcott⁵, David Gruben⁶, Christopher W Murray⁵, Noriko Iikuni⁴, Andrew Koenig⁵ and James Harnett⁴, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Institut de Rhumatologie de Montreal, Montreal, QC, Canada, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA, in combination with MTX or other non‑biologic (nb)DMARDs, or as monotherapy. Two…
Abstract Number: 2348 • 2018 ACR/ARHP Annual Meeting
Prescriber Attitudes and Beliefs about Triple Therapy for Patients with Rheumatoid Arthritis: Knowledge Exchange in Internet Forums and Social Media
Maria A. Lopez-Olivo¹, Jude K. A. des Bordes¹, Gregory Pratt² and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, ²Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX
Background/Purpose: Several forums on the internet serve as repositories of personal experiences and exchange of health information. Online discussions among healthcare providers about management of…
Abstract Number: 583 • 2018 ACR/ARHP Annual Meeting
Identification of a Protein Profile Useful to Predict Response to Methotrexate in Early Rheumatoid Arthritis Patients
Cristina Ruiz-Romero¹, Florencia Picchi², Lucia González², Rebecca Hands³, Valentina Calamia², Patricia Fernández⁴, Maria Camacho², Rocío Paz², Conrad Bessant⁵, Costantino Pitzalis³ and Francisco J Blanco⁶, ¹Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ²Rheumatology Research Group, Proteomics Unit-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, Spain, ³Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ⁴Proteomics group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, La Coruña, Spain, ⁵School of Biological and Chemical Sciences, Queen Mary University of London, London, United Kingdom, ⁶Rheumatology Divison, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain
Background/Purpose: Among the best known disease-modifying antirheumatic drugs, Methotrexate (MTX) is one of the most effective and widely used medications. It is used as a…
Abstract Number: 2353 • 2018 ACR/ARHP Annual Meeting
Attitudes and Beliefs Regarding Methotrexate in Patients with Rheumatoid Arthritis: Results from Australian Rheumatology Association Database
Nieves Leonardo^1,2, Susan Lester^3,4, Michelle Graham⁵, Samuel Whittle^1,6, Debra Rowett^7,8, Rachelle Buchbinder^9,10 and Catherine Hill^6,11,12, ¹Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia, ²Rheumatology, The Queen Elizabeth Hospital, Adelaide, Australia, ³Rheumatology Unit, The Queen Elizabeth Hospital, Adelaide, Australia, ⁴Discipline of Medicine, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia, ⁵Arthritis Queensland, Queensland, Australia, ⁶The Queen Elizabeth Hospital, Adelaide, Australia, ⁷School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia, ⁸Drug and Therapeutics Information Service, Southern Adelaide Local Health Network, Adelaide, Australia, ⁹Cabrini Institute, Victoria, Australia, ¹⁰Monash University, Melbourne, Australia, ¹¹Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ¹²Medicine, The University of Adelaide, Adelaide, Australia
Background/Purpose: To determine beliefs about methotrexate (MTX) in patients with Rheumatoid Arthritis (RA) in relation to views obtained from a range of information sources.Methods: RA…
Abstract Number: 585 • 2018 ACR/ARHP Annual Meeting
The Role of Genetic Polymorphisms on the Response to Methotrexate Variations Among Rheumatoid Arthritis Patients in Saudi Arabia
Suzan Attar¹, Magdah Hagrass², Adel Abuzenadah³, Omar Fath Aldin¹, Rahaf Attar⁴, Rajaa Al-Raddadi⁵, Mansour Sulaiman² and Ahmed Aseri², ¹Internal Medicine, Department of Internal Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, ²Pharmacology, Department of Pharmacology, King Abdulaziz University, Jeddah, Saudi Arabia, ³medical technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia, ⁴internal medicine, Department of Internal Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, ⁵Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
Background/Purpose: Low dose methotrexate (MTX) is one of the most commonly used disease-modifying anti-rheumatic drug for rheumatoid arthritis (RA) with excellent efficacy and safety profile. However, it…
Abstract Number: 2369 • 2018 ACR/ARHP Annual Meeting
Patients Preference Goes to MTX Autoinjectors over Prefilled Syringes: Results from a Phase III Trial
Alain Saraux¹, Christophe Hudry², Elena Zinovieva³, Agnès Courbeyrette⁴ and Hélène Herman-Demars³, ¹Rheumatology, CHU Brest, Brest, France, ²AP-HP Hôpital Cochin, Paris, France, ³Medical Department Nordic Pharma, Paris, France, ⁴Medical Departement, Nordic Pharma, Paris, France
Background/Purpose: The offer of injectable MTX worldwide expanded during past few years with different types of enhanced devices such as prefilled syringes and autoinjector pens.…
Abstract Number: 601 • 2018 ACR/ARHP Annual Meeting
At Which Point and for Which Reasons Are Oral MTX Formulations Switched to Injectable Ones in RA Patients? Combined Results from 3 Independent Observational and Clinical Trials
René-Marc Flipo¹, Alain Saraux², Christophe Hudry³, Cécile Gaujoux-Viala⁴, Eric Senbel⁵, Sonia Tropé⁶, Elena Zinovieva⁷, Agnès Courbeyrette⁸ and Hélène Herman-Demars⁷, ¹Hôpital Roger Salengro, Lille, France, ²Rheumatology, CHU Brest, Brest, France, ³AP-HP Hôpital Cochin, Paris, France, ⁴Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France, ⁵Rheumatology office, Marseille, France, ⁶149 avenue du Maine, ANDAR, Paris, France, ⁷Medical Department Nordic Pharma, Paris, France, ⁸Medical Departement, Nordic Pharma, Paris, France
Background/Purpose: MTX is considered as a cornerstone in RA treatment since the 1990s and its injectable forms have proven their enhanced clinical and pharmacological efficacy…
Abstract Number: 2446 • 2018 ACR/ARHP Annual Meeting
The Combined Use of Folic Acid Influenced the Time until the Development of Lymphoproliferative Disorders in Patients with Rheumatoid Arthritis during Treatment with Methotrexate
Sho Sasaki¹, Yasushi Kondo², Yasuo Suzuki³, Takayoshi Kurabayashi¹, Yasushi Koyama¹, Yuto Izumi¹, Yoko Nakagome¹, Kazuki Hirano¹, Chiho Yamada¹ and Shinji Sato¹, ¹Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, ²Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Tokai University Hachioji Hospital, Hachioji, Japan, Isehara, Japan
Background/Purpose: Lymphoproliferative disorders (LPDs) are a serious complication in patients with rheumatoid arthritis (RA). Methotrexate (MTX) is known to be able to cause a development…
Abstract Number: 611 • 2018 ACR/ARHP Annual Meeting
Influence of Dose Titration of Concomitant Steroid and Methotrexate during Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice Based on the IORRA Cohort
Yoko Shimizu¹, Eiichi Tanaka¹, Eisuke Inoue^1,2, Kumiko Saka¹, Eri Sugano¹, Naohiro Sugitani^1,3, Moeko Ochiai¹, Rei Yamaguchi¹, Naoki Sugimoto¹, Ayako Nakajima^1,3, Katsunori Ikari¹, Atsuo Taniguchi¹ and Hisashi Yamanaka⁴, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, ³Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, ⁴Institute of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: After the introduction of Biological Disease-Modifying Anti-Rheumatic-Drugs (bDMARDs) for the treatment of patients with active rheumatoid arthritis (RA), clinical remission has become an achievable…
Abstract Number: 2486 • 2018 ACR/ARHP Annual Meeting
Real-World Outcomes Associated with Triple Therapy Vs. TNFi Combo Therapy: Results from the Corrona Registry
Jeffrey R. Curtis¹, J. Lynn Palmer², George W. Reed³, Jeffrey Greenberg⁴, Dimitrios A. Pappas⁵, Leslie R Harrold⁶ and Joel Kremer⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Corrona Research Foundation, Albany, NY, ³UMass Medical School, Worcester, MA, ⁴Corrona LLC, Waltham, MA, ⁵Columbia University, New York, NY, ⁶University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Despite several randomized controlled trials showing comparable clinical outcomes with triple therapy (Triple; MTX, SSZ, HCQ) versus combination therapy with MTX+TNFi (TNFi Combo), the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].